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Abstract
Background: Nodular follicular lesions of thyroid gland comprise benign and malignant neoplasms, as well as
some forms of hyperplasia. “Follicular” refers to origin of cells and in the same time to growth pattern - building
follicles. Nodular follicular thyroid lesions have in common many morphological features, therefore attempts were
made to define additional criteria for distinction between follicular adenoma, follicular carcinoma and follicular variant
of papillary carcinoma. Increasing number of immunohistochemical markers is in the continual process of evaluation.
Methods: Tissue microarrays incorporating, total 201 cases, out of which 122 malignant and 79 benign follicular
lesions, including neoplastic and non-neoplastic, were constructed and immunostained with antibodies to CD56,
CK19, Galectin-3, HBME-1. Tissue cores were exclusively being acquired from tumour/lesion on interface with
normal thyroid tissue. A systematic review of literature was done for period from the year 2001 to present time.
Results: All analysed markers may make a difference between benign lesions/tumours from differentiated thyroid
carcinomas (p = <0.01, for all markers). Expression of all markers is significantly higher in papillary carcinoma than
in follicular adenoma (p < 0.01). Statistically significant difference in expression of Galectin-3 and CD56 between
follicular carcinoma and follicular adenoma was registered (p = 0.043; p = 0.028, respectively). The only marker
which expression showed statistically significant difference between adenoma and carcinoma of Hurthle cells was
Galectin 3 (p = 0.041). CK19 and HBME-1 were significantly expressed more in papillary carcinoma as compared to
follicular carcinoma.
Conclusion: Galectin 3 is most sensitive marker for malignancy, while loss of expression of CD56 is very specific
for malignancy. Expected co-expression for combination of markers in diagnosis of follicular lesions decreases
sensitivity and increases specificity for malignancy.
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Background
Pathology of thyroid gland is diverse. Nevertheless, from
practical reasons, all lesions can be divided into two
groups, with nodular and diffuse pattern of growth. The
former group clinically manifested as thyroid nodules,
comprise benign and malignant neoplasms, as well as
some forms of hyperplasia [1].
Nodules of thyroid gland are very frequent. It was
estimated that 5 % of general population develop clinic-
ally obvious nodule. With introduction of better ultra-
sound facilities, the detection of non palpable nodules
is on the rise, 20–67 % of detected non palpable thyroid
nodules [2].
Term “follicular” in thyroid gland has dual connota-
tion, to have origin from follicular cells or building fol-
licles (designating follicular pattern of growth). Lesions
with follicular growth pattern could be further classified
relative to size of follicles (micro-, macrofollicular), or
in respect to presence of capsule (totally /partially en-
capsulated, non encapsulated). Universally, majority of
follicular lesions could be classified into benign and
malignant category. According to presence or absence
of features in parenthesis (capsule, vascular/capsular
invasion, papillary carcinoma type nuclei) we classify
them as: adenomatoid nodules and adenomas, papillary
thyroid carcinoma (PTC), follicular thyroid carcinoma
(FTC), well differentiated tumours of uncertain malignant
potential (WDT-UMP), follicular tumour of uncertain ma-
lignant potential (FT-UMP), well differentiated carcinoma,
NOS, Hurthle cell adenoma/carcinoma [3–7]. Follicular
nodular thyroid lesions have in common many morpho-
logical features, which frankly put a burden on pathologist
while trying to make diagnosis on H&E slides. Even
amongst experienced endocrine pathologist there exists
inter-observer variability. Furthermore, intra-observer
variability is seen when they review the same H&E
slides after some period of time [8].
Attempts were made to define additional criteria for
distinction of follicular adenoma (FA) from follicular
carcinoma and follicular variant of papillary carcinoma,
and between two later mentioned. Increasing number
of immunohistochemical markers are being tested, and
some are promising like CD56, Hector Battifora Mesothe-
lial 1 (HBME-1), Galectin 3 (Gal-3) and Cytokeratin 19
(CK19) considering differential diagnosis, nevertheless,
none of them is individually conclusive [6, 9].
The aim of this study was to test sufficient number of
different follicular thyroid lesions using for that purpose
tissue microarray (TMA) technology, exploiting all four
above mentioned markers. Our intention is to try to ob-
tain answers to following questions: Can they distinct
benign from malignant lesions?; Can they differentiate
between papillary carcinoma (especially follicular vari-
ant) from follicular carcinoma or adenoma; Could they
differentiate follicular adenoma from follicular carcin-
oma? We hypothesized that not just one combination
but acceptable number of well-tailored combinations of
immunohistochemical markers should suit for different
differential diagnostic combinations. Elaborated review
of literature on expression of CD56, CK19, HBME-1,
Gal-3 is also provided.
Methods
Case selection
This retrospective study was conducted on 201 cases of
thyroid lesions, including 44 males and 157 females.
Majority of cases were from 2013th, and 2014th, but due
to the paucity of cases with follicular thyroid carcin-
oma, aforementioned cases were selected retrospect-
ively all the way till the year of 2007th. The research
was approved by Ethical committee of Medical Faculty,
University in Belgrade. Cases were selected from ar-
chives of Department for endocrine pathology, Center
for endocrine surgery, Clinical centre of Serbia. Glass
slides (on average 7 per case) were retrieved and evalu-
ated by three experienced endocrine pathologists, who
were unaware of clinical information and previous diag-
nosis. Diagnosis for problematic cases was made by
consensus of two pathologists. Examination comprised
122 malignant and 79 benign follicular lesions. Only tu-
mours with diameter larger than 5 mm were included
in the study.
TMA
Four high density TMAs were constructed manually.
Area of interest was the zone right beneath tumour cap-
sule or just on invasive tumours front. Previously
marked area of interest on slides was translated to corre-
sponding regions of donor paraffin blocks. Needle with
inner diameter of 1.1 mm was used to create and trans-
fer tissue cores (0.785 mm2 cross cut surface area) in re-
cipient paraffin blocks. Two cores were taken from every
lesion. Cases with at least one section across all slides
were regarded as valid. Tissue cores with external con-
trols were included in all TMAs. Final TMA blocks con-
sisted of 104 cores (13x8), plus five control tissue cores.
Control tissues included in TMA were normal thyroid
tissue, follicular thyroid adenoma, mucosa of appendix
(crypts positive to CK19 and Gal-3), serous membrane of
appendix (mesothelial cell immunopositive for HBME-1),
muscular layer of appendix (nerve fibers and ganglion
cells positive for CD56).
Immunohistochemistry
Immunohistohemical staining with CD56 (NOVOCAS-
TRA, Clone 1B6, 1:50), HBME-1 (DAKO, Clone HBME-
1, 1:50), CK19 (DAKO, Clone RCK 108, 1:50), Galectin-3
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(R&D SYSTEMS, Clone 194804, 1:100) was done manu-
ally according to manufacturers instructions (Table 1).
Evaluation of immunohistochemical staining
Cytoplasmatic ± nuclear immunoreactivity for Gal-3, mem-
branous ± cytoplasmatic immunoreactivity for CK19, and
membranous ± cytoplasmatic immunoreactivity for HBME-
1 in more than 10 % of cells was considered as positive
staining without regard to intensity of staining. In respect
to distribution of staining we graded staining as 1, 2, 3, 4,
when 11–25 %, 26–50 %, 51–75 %, 76–100 % of tumours
cells show expression, respectively [10].
Membranous staining of follicular cells with CD56 was
regarded as positive. On the grounds that CD56 expres-
sion is reduced or missing in thyroid carcinomas, posi-
tive result (or malignant profile) was scored as 1 when
0–10 % follicular cells is immunoreactive for CD56.
Score 0 (negative) was in the case that equal or more
than 11 % of follicular cells were positive for CD56 [11].
Statistical analysis
Database and data analyses were done with IBM SPSS
Statistics 20. Descriptive and analytical methods were
used. For comparison of variables, parametric (t test,
ANOVA) and non-parametric tests (chi square, Mann
Whitney U test, Kruskal Wallis test) were employed.
With objective to compare markers Receiver Operating
Curve (ROC) was constructed. Sensitivity, specificity,
positive and negative predictive values, and diagnostic
odds ratio were calculated for single and combination of
markers in program MedCalc® (Version 10.2.0.0). Prob-
ability values less than 0.05 were considered statistically
significant.
Review of literature
Review of literature was done in PUBMED for period
from the year 2001 to present time. The following de-
scribers were used ((CK-19 and thyroid) OR (GALEC-
TIN-3 and thyroid) OR (HBME-1 and thyroid) OR
(CD56 and thyroid). We included studies which contain
benign as well as malignant cases, and which employ tis-
sue immunohistochemistry as technique. The following
information was acquired: reference, number of benign
and malignant cases, histological types of neoplasms
studied and results (stratified into two groups: true posi-
tive, true negative, false positive, false negative). Our re-
sults were compared with different studies.
Results
Average age of patients was 51 ± 14 years, with median
of 53. Comparing benign with malignant group, matched
relative to sex, and relative to age, we found no statis-
tical difference between groups (p = .134; p = .051, re-
spectively). The mean size of benign and malignant
lesions was 3.3 cm (range, 0.5 to 9.0 cm) and 3.4 cm
(range 0.5 to 12.0 cm), respectively (p = .719). Malignant
group consisted of 87 papillary thyroid carcinomas, 15
follicular thyroid carcinomas and 20 Hurthle cell carcin-
omas. Benign lesions included 27 follicular adenomas,
10 Hurthle cell adenomas, 12 hyperplastic adenomas,
and 30 nodular goiters (colloid adenomas). The group of
papillary carcinomas was represented by 40 follicular
type, 27 classic type, 9 mixed, 5 solid and 3 oxyphilic
type carcinomas.
CK19 expression was present in 75 % of malignant tu-
mours, generally with high intensity and wide distribu-
tion, and in 29.1 % of benign lesion, usually with weak
and focal expression (p = .000) (Tables 2 and 3). Immu-
noreactivity was cytoplasmatic, sometimes with mem-
branous accentuation (Fig. 1). Among carcinomas,
difference in expression of CK19 existed between papil-
lary carcinoma and follicular carcinoma (p = .000). Dif-
ferences in expression were significant between papillary
carcinoma and follicular adenoma (p = .000), as well as
between follicular variant of papillary carcinoma and fol-
licular carcinoma (p = .004) or adenoma (p=. 000). When
we excluded papillary carcinoma from the sample we
found statistical significance between malignant and be-
nign group (p = 0.045). Significant difference in expres-
sion of CK19 was not found between follicular adenoma
and follicular carcinoma (p = .433), or between Hurthle
cell adenoma/carcinoma (p = .894). ROC curve (Fig. 2)
was constructed, and value higher than 9.5 % of positive
Table 1 Immunohistochemistry
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tumours cells had sensitivity of 75.4 %, and specificity
71 % for carcinoma (Table 4).
Malignant tumors expressed intensively and widely
HBME-1 antigen than benign lesions (71.3 %; 15,2 %,
respectively; p = .000). Variation in immunoreactivity
was significant between papillary and follicular carcin-
oma (p = .000), papillary carcinoma and follicular aden-
oma (p = .000), and between follicular variant of
papillary carcinoma and follicular carcinoma/adenoma
(p = .009; p = .000 respectively). Once again, no signifi-
cant difference was found comparing follicular adenoma/
carcinoma (p = .465) in respect to HBME-1 expression.
The values equal or higher than 7.5 % of follicular cells
immunoreactive for HBME-1 had sensitivity of 71.3 % and
specificity of 85 % for carcinoma.
Galectin-3 was expressed significantly more in malig-
nant tumours (88.5 %) than in benign (35.4 %) (p = .000).
Further, expression of Galectin-3 in papillary carcinoma
and follicular variant of papillary carcinoma was notably
higher than in follicular adenoma (p = .000; p = .001;
respectively). We found no difference in expression
between papillary and follicular carcinoma (p = 0.171),
nor between follicular variant of papillary carcinoma and
follicular carcinoma (p = 0.691). At last, follicular
carcinoma had higher expression than follicular aden-
oma (0.043) and Hurthle cell carcinoma than Hurthle
cell adenoma (p = 0.041). With cut off value of 7.5 % of
follicular cells expressing Galectin-3, sensitivity is 89 %,
and specificity is 65 % for carcinoma.
CD56 expression was lost in 58.2 % of malignant le-
sions and 7.6 % of benign lesions (p = .000). Papillary
carcinoma lost expression in 74.7 % of cases, compared
to follicular carcinomas 26.7 % (p = .006), and follicular
adenoma 3.7 % (p = .000). No statistically significant dif-
ference in expression was observed between follicular
variant of papillary carcinoma and follicular carcinoma
(p = .282), but there is a difference between follicular
variant of papillary carcinoma and follicular adenoma
(p = .000). Interestingly, difference also existed between
follicular carcinoma and follicular adenoma (p = 0.028),
and between follicular carcinoma and benign thyroid
lesions (without Hurthle cell adenomas; p = 0.006) Hav-
ing insight in ROC coordinates, the values less than
12.5 % of follicular cells expressing CD56, have sensitiv-
ity of 58 % and specificity of 92.4 % for carcinoma.
Diagnostic value of all investigated markers and their
combinations in differentiating malignant from benign
thyroid follicular lesions was presented in a form of
sensitivity, specificity, positive and negative likelihood
ratios, disease prevalence, positive and negative predict-
ive values, and odds ratio (Tables 5 and 6). Sensitivity
and specificity for different combinations of markers in
respect to various histopathological entities were pre-
sented in Table 7.
Review of literature was presented within tables (Tables 8,
9, 10, 11 and 12). Sensitivity and specificity for different
combinations of entities, taking into account all available
cases from reviewed studies, including current study is dis-
cussed (Table 13).
Discussion
This tissue microarray based study is a unique in a
methodological way because it gives information of ex-
pression of investigated markers on tumour front. It




N % N %
CK 19 + 23 29.1 % 92 75.4 %
- 56 70.9 % 30 24.6 %
HBME 1 + 12 15.2 % 87 71.3 %
- 67 84.8 % 35 28.7 %
Galectin 3 + 28 35.4 % 108 88.5 %
- 51 64.6 % 14 11.5 %
CD 56 + 6 7.6 % 71 58.2 %
- 73 92.4 % 51 41.8 %




CK 19 HBME 1 Galectin 3 CD 56a
N % N % N % N %
Colloid adenoma 30 11 36.7 % 1 3.3 % 4 13.3 % 4 86.70 %
Follicular adenoma 27 6 22.2 % 4 14.8 % 11 40.7 % 1 96.30 %
Hurthle cell adenoma 10 6 60.0 % 7 70.0 % 5 50.0 % 1 90.00 %
Hyperplastic adenoma 12 0 0.0 % 0 0.0 % 8 66.7 % 0 100.00 %
Follicular carcinoma 15 5 33.3 % 4 26.7 % 11 73.3 % 4 73.30 %
Hurhle cell carcinoma 20 12 60.0 % 17 85.0 % 17 85.0 % 2 90.00 %
Papillary carcinoma 87 75 86.2 % 66 75.9 % 80 92.0 % 65 25.30 %
aimmunopositivity in >10 % follicular cells
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provides answers to questions asked in introductory part
of this paper. We provided the readers with extensive re-
view of literature on the subject, with fast insights in
methodological approach, cut off values and results of
reviewed studies.
All analysed immunomarkers may make a difference
between benign lesions/tumours from differentiated thy-
roid carcinomas. CK19 and HBME-1 can differentiate
between papillary carcinoma and follicular carcinoma.
Expression of all markers is significantly higher in papil-
lary carcinoma than in follicular adenoma. Galectin-3
could not distinct papillary from follicular carcinoma.
CD56 and Galectin-3 could not differentiate between
follicular variant of papillary carcinoma and follicular
carcinoma. Interestingly, Galectin-3 and CD56 made sta-
tistically significant difference between follicular carcin-
oma and follicular adenoma. The only marker which
makes statistically significant difference between aden-
oma and carcinoma of Hurthle cells was Galectin 3. Best
balanced marker in our study, in terms of sensitivity and
specificity for malignancy, was HBME-1. The most sen-
sitive marker was Galectin 3, and the most specific
marker in our study was CD56. Former mentioned
marker, at the same time, had the lowest specificity, and
latter had the lowest sensitivity of all. When we com-
bined two, three or four co-expressed markers, we did
not reach specificity of 100 % for malignancy, nonethe-
less values increased compared to single marker expres-
sion. On the other hand, the unfavourable result was
lowering of sensitivity for malignancy, compared with
use of single marker. The best combination of co-
expressing markers for identifying malignancy was
HBME-1 and Gal-3. Best discriminatory combinations of
markers for papillary carcinoma from follicular aden-
oma, and non-neoplastic lesions were CD56 with Galec-
tin 3, and CK19 with Galectin 3, respectively. For
discriminating follicular variant of papillary carcinoma
from follicular adenoma or carcinoma, best combina-
tions were CK19 with Galectin 3, and CD56 with
HBME1, respectively.
Cytokeratin 19 is the smallest member of cytokeratins
family, a heterogeneous group of intermediate fila-
ments. Physiologically, it is expressed in simple and
glandular epithelia, basal layer of stratified epithelium,
and in hair follicles [12]. Healthy thyroid follicular cells
do not produce this protein, and upregulation of CK19
is connected with neoplastic transformation. Strong
and diffuse immunoreactivity of CK19 is most often re-
lated to papillary thyroid carcinoma [13].
Our result show that CK19 is overexpressed in papil-
lary thyroid carcinoma, diffusely and intensively in most
cases. Overexpression of this marker is related not just
to PTC, but to malignancy. Discouraging thing, is that
serious number of benign cases also expressed CK19, al-
though focally and weakly. Only hyperplastic adenomas
were completely negative in our investigation.
We reviewed 23 papers [10, 11, 14–34], and than
recalculated average sensitivity and specificity for carcin-
omas (80 %, 78 % respectively). The results of our study
Fig. 1 Expression of CD56, CK19, HBME-1, Galectin-3 in folicular
adenoma and follicular variant of papillary carcinoma. a membranous
immunoexpression of CD56 in follicular adenoma; (b): absence of
immunoexpression of CK19 in follicular adenoma; (c): absence of
immunoexpression of HBME-1 in follicular adenoma; (d): absence
of imunoexpression of Galectin-3 in follicular adenoma; (e): loss of
immunoexpression of CD56 in follicular variant of papillary thyroid
carcinoma; (f): membranous and cytoplasmatic immunoexpression of CK
19 in follicular variant of papillary thyroid carcinoma; (g): membranous
and cytoplasmatic immunoexpression of HBME-1 in follicular variant of
papillary thyroid carcinoma; (h): cytoplasmatic immunoexpression of
Galectin-3 in follicular variant of papillary thyroid carcinoma
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are in concordance with the results from majority of pa-
pers we have reviewed. Sensitivity values varied from 13
to 100 % (mediansens = 84 %), while specificity values var-
ied from 0 to 100 % (medianspec = 75 %) (see Table 9).
Control group non tumor tissues, follicular adenoma,
follicular carcinoma, and papillary carcinoma had
positive expression of this marker which varied from
study to study: 4–89 % (median = 20 %); 0–100 % (me-
dian = 24 %); 0–50 % (median = 40 %); 46–100 % (me-
dian = 95 %), respectively.
Generally, studies showed that CK19 is more expressed
in malignant lesions than in benign follicular cells derived
Fig. 2 ROCs for CK19, HBME-1, Galectin-3, CD56. ROC Curve: receiver operating characteristic (ROC) curve
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thyroid lesions [14, 15]. The expression of CK19 in papil-
lary carcinoma (general) and follicular variant PTC was
significantly higher than in follicular thyroid carcinoma
(FTC) [15]. Further, it can serve to differentiate papillary
thyroid carcinoma from follicular adenoma [31], but can
not help in differentiation between follicular adenoma and
follicular carcinoma [30, 10]. Also, it does not make differ-
ence between follicular carcinoma and normal tissue [26].
In the end, we may make few conclusions: CK19 can
help in diagnosis of papillary thyroid carcinoma, but
one must take into account the intensity and distribu-
tion of marker within the tumour; CK19 intensive im-
munoreactivity, plus missing criteria for PTC, should
alert on possibility of malignancy; due to its relatively
low specificity, we recommend the use of marker in
combination with others.
HBME1 (Hector Battifora Mesothelial 1), is monoclo-
nal antibody which reacts with uncharacterized antibody
in microvilli of mesothelial cells. HBME-1 has been
assessed in thyroid with the aim to help in differenti-
ation of benign from malignant lesions.
HBME-1 is more expressed in malignant lesions com-
pared to benign lesions [10, 14, 15, 18, 23, 25, 32, 35].
Benign lesions expressed HBME-1 focally, rather than dif-
fusely. It is more extensively expressed in papillary carcin-
omas compared to follicular carcinomas and follicular
adenomas [18, 25]. Follicular variant of papillary carcin-
oma has significantly higher expression of this marker
than follicular adenoma or follicular carcinoma [25, 31].
The aforementioned studies and their results are in con-
cordance with our study. The results of a few other studies
were showing higher expression of HBME-1 in follicular
carcinoma than in follicular adenoma. [10, 27, 32, 35],
which is not the case with results of our study and some
other studies [15, 25, 31]. When we pulled out all the re-
sults of expression of HBME-1 in follicular adenomas and
follicular carcinomas from reviewed studies, and made
comparison of those two groups, we have obtained signifi-
cant difference in expression between two above men-
tioned groups (Fisher’s exact test, the two-tailed P value is
less than 0.0001).
Among 25 reviewed studies [10, 11, 14–19, 22–25,
27, 28, 31, 32, 34–42], the sensitivity and specificity of
this marker varied markedly (34–100 % for sensitivity,
54–100 % for specificity), with average sensitivity of
76 % and specificity of 87 % for carcinomas compared
to benign lesions (mediansens = 77 %; medianspec =
89 %). Control non tumor tissues showed positive ex-
pression of this marker in the range 0–35 % (median =
10 %) of cases. Follicular adenomas, follicular carcin-
omas and papillary carcinomas through the studies
show positive expression in given ranges: 0–56 % (me-
dian = 25 %); 17–100 % (median = 65 %); 55–100 %
(median = 92 %), respectively. The increasing trend of
expression is noticeable, starting from non-tumour tis-
sues to papillary carcinomas.
Simultaneous immunopositivity for HBME-1 and Galec-
tin 3, and HBME-1 and CK19 in the diagnosis of differenti-
ated thyroid carcinoma have sensitivities of 85,9 %, and
86.4 % respectively, and specificities of 100 % for both com-
binations. Specificities values increased, but sensitivities
values decreased comparing to single markers values [10].
Co-expression of HBME1 and CK19 has a sensitivity
of 83 % and specificity of 100 % of diagnosing papillary
carcinoma compared to follicular adenoma. Opposite,
the HBME1-CK19 negative staining for both markers
was highly indicative of follicular adenoma (99 % specifi-
city and 82 % sensitivity) [16].
The combined use of HBME-1 and Gal-3 was able to
improve sensitivity up to 99 % and specificity up to 80 %
in diagnosis of malignant Hurthle cell tumours com-
pared to Hurthle cell adenomas [41].
Table 5 Diagnostic value of tests in discrimination of malignant
from benign thyroid lesions
For malignancy HBME-1 Galectin-3 CK19 CD56
Sensitivity 71.31 % 88.52 % 75.41 % 58.20 %
Specificity 84.81 % 64.56 % 70.89 % 92.41 %
Positive Likelihood Ratio 4.69 2.5 2.59 7.66
Negative Likelihood Ratio 0.34 0.18 0.35 0.45
Disease prevalence 60.70 % 60.70 % 60.70 % 60.70 %
Positive Predictive Value 87.88 % 79.41 % 80.00 % 92.21 %
Negative Predictive Value 65.69 % 78.46 % 65.12 % 58.87 %
Odds ratio 13.8786 14.051 7.4667 16.9379







Asymptotic 95 % Confidence Interval
Lower Bound Upper Bound
CK19 .786 .032 .000 .723 .848
HBME-1 .842 .028 .000 .788 .896
Galectin-3 .841 .028 .000 .786 .897
CD56 .799 .031 .000 .739 .860
aUnder the nonparametric assumption
bNull hypothesis: true area = 0.5
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Table 6 Diagnostic value of markers combinations (all markers in combination positive) in discrimination of malignant from benign thyroid lesions














Sensitivity 50.82 % 50.00 % 52.46 % 60.66 % 68.03 % 64.75 % 45.90 % 54.92 % 45.08 % 45.08 % 40.16 %
Specificity 94.94 % 98.73 % 97.47 % 89.87 % 88.61 % 92.41 % 97.47 % 93.67 % 98.73 % 98.73 % 98.73 %
Positive Likelihood
Ratio
10.04 39.5 20.72 5.99 5.97 8.53 18.13 8.68 35.61 35.61 31.73
Negative
Likelihood Ratio
0.52 0.51 0.49 0.44 0.36 0.38 0.56 0.48 0.56 0.56 0.61
Disease prevalence 60.70 % 60.70 % 60.70 % 60.70 % 60.70 % 60.70 % 60.70 % 60.70 % 60.70 % 60.70 % 60.70 %
Positive Predictive
Value
93.94 % 98.39 % 96.97 % 90.24 % 90.22 % 92.94 % 96.55 % 93.06 % 98.21 % 98.21 % 98.00 %
Negative Predictive
Value












Galectin 3 is a structurally unique member (31-kDa)
of galectins family. Galectin-3 is capable to make cross
links with cell membrane glycoproteins, thus forming
new network involved in cellular signaling and receptors
endocytosis. Galectin 3 is detected in nucleus, cytoplasm
and in extra cellular space. Galectin 3 plays roles in
apoptosis regulation, cell motility, and it is involved in
thyroid carcinoma progression [43, 44].
Long ago, Xu et al. [44], had been investigating ex-
pression of Galectin 1 and Galectin 3 in small series of
thyroid tumours, and they had found expression in
papillary and follicular carcinomas, but not in aden-
omas, nodular goiter, nor in normal thyroid tissue. On
the grounds of those investigations they deduced that
galectins could bu useful in making distinction between
benign and malignant thyroid tumours [44].
Expression of Galectin 3 is higher in malignant com-
pared to benign thyroid lesions [10, 14, 15, 18, 23, 25, 35].
Some authors found difference in expression of Galectin 3
between papillary carcinoma, and its follicular variant,
compared to follicular carcinoma [10, 25, 31]. Neverthe-
less, others have not found those differences, including
here the results of our study too [15, 35]. Galectin 3 have
been found to have higher immunoreactivity in papillary
(also follicular variant) carcinoma compared to follicular
adenoma [15, 25, 27, 31, 35], which is comparable to our
results. Few studies, including the current, found differ-
ence in expression of Galectin 3 between follicular carcin-
oma and follicular adenoma [10, 35]. Galectin 3 was the
only marker able to make a difference between Hurthle
cell carcinoma and adenoma, which is also confirmed by
the study of Volante M et al. [41].
Having made insight in data from reviewed studies
[15–19, 23–32, 35, 36, 41, 45–60], once again, we have
noticed high variability in sensitivity and specificity for
carcinoma of this marker. The values of sensitivity have
Table 7 Sensitivity and specificity values of different markers combinations for different combinations of PH entities
All markers in combination were positive
Sensitivity & Specificity for first in comparison
Malign Benign PTC vs FA FVPTC vs FA FVPTC vs FTC FTC vs FA PTC vs non-tumor HCC vs HCA
CD56_CK19 Sensitivity 50.8 % 65.5 % 50.0 % 50.0 % 20.0 % 65.5 % 10.0 %
Specificity 94.9 % 100 % 100.0 % 85.7 % 100.0 % 92.9 % 90.0 %
CD56_HBME1 Sensitivity 50.0 % 65.5 % 55.0 % 55.0 % 13.3 % 65.5 % 10.0 %
Specificity 98.7 % 100 % 100.0 % 92.9 % 100.0 % 100.0 % 90.0 %
CD56_GAL3 Sensitivity 52.5 % 69 % 57.5 % 57.5 % 20.0 % 69.0 % 5.0 %
Specificity 97.5 % 100 % 100.0 % 85.7 % 100.0 % 97.6 % 90.0 %
HBME1_CK19 Sensitivity 60.7 % 67.8 % 52.5 % 52.5 % 20.0 % 67.8 % 60.0 %
Specificity 89.9 % 92.6 % 92.6 % 85.7 % 92.6 % 97.6 % 50.0 %
GAL3_HBME1 Sensitivity 64.8 % 70.1 % 60.0 % 60.0 % 20.0 % 70.1 % 75.0 %
Specificity 92.4 % 96.3 % 96.3 % 85.7 % 96.3 % 97.6 % 60.0 %
CK19_GAL3 Sensitivity 68.0 % 78.2 % 70.0 % 70.0 % 33.3 % 78.2 % 50.0 %
Specificity 88.6 % 88.9 % 88.9 % 71.4 % 88.9 % 92.9 % 70.0 %
CD56_CK19_HBME1 Sensitivity 45.1 % 58.6 % 45.0 % 45.0 % 13.3 % 58.6 % 10.0 %
Specificity 98.7 % 100 % 100.0 % 92.9 % 100.0 % 100.0 % 90.0 %
CD56_GAL3_HBME1 Sensitivity 45.1 % 59.8 % 50.0 % 50.0 % 13.3 % 59.8 % 5.0 %
Specificity 98.7 % 100 % 100.0 % 92.9 % 100.0 % 100.0 % 90.0 %
CD56_GAL3_CK19 Sensitivity 45.9 % 59.8 % 45.0 % 45.0 % 20.0 % 59.8 % 5.0 %
Specificity 97.5 % 100 % 100.0 % 85.7 % 100.0 % 97.6 % 90.0 %
HBME1_GAL3_CK19 Sensitivity 54.9 % 62.1 % 47.5 % 47.5 % 20.0 % 62.1 % 50.0 %
Specificity 93.7 % 96.3 % 96.3 % 85.7 % 96.3 % 97.6 % 70.0 %
CD56_HBME1_GAL3_CK19 Sensitivity 40.2 % 52.9 % 40.0 % 40.0 % 13.3 % 52.9 % 5.0 %
Specificity 98.7 % 100 % 100.0 % 92.9 % 100.0 % 100.0 % 90.0 %
FA follicular adenoma, HA Hurthle cell adenoma, FTC follicular thyroid carcinoma, HCC Hurthle cell carcinoma, FVPTC folicular variant of papillary thyroid
carcinoma, non-tumor (hyperplastic and colloid adenomas)
Table 8 Number of studies, patients and their distributions
included in each analysis by the immunohistochemistry
technique
Studies Patients TP FP FN TN
CK19 24 4239 1834 436 464 1505
CD56 10 1226 158 418 619 31
HMBE-1 26 4691 1824 311 563 1993
GALECT 3 38 5426 2344 442 458 2182
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Table 9 Sensitivity and specificity of CK 19 for malignancy, plus total number and percent of cases with positive immunoexpression
Reference Benign Malignant NG FA HA HCA FTC PTC HCC FVPTC Sens Spec Cut off TMA Total
N % N % N % N % N % N % N % N % N % N %
Dunđerović (2015) 79 29 % 122 75 % 30 37 % 27 22 % 12 0 % 10 60 % 15 33 % 87 86 % 20 60 % 40 78 % 75 % 71 % 10 % yes 201
Barroeta (2006) [14] 53 34 % 37 70 % 4 25 % 3 0 % 18 17 % 3 0 % 7 43 % 11 91 % 4 25 % 4 100 % 70 % 66 % 25 % yes 90
Zhu X (2010) [15] 58 26 % 180 79 % 17 12 % 21 14 % 11 27 % 155 87 % 7 86 % 79 % 74 % 5 % no 238
Park YJ (2007) [10] 89 17 % 206 90 % 54 9 % 35 29 % 25 44 % 181 98 % 17 100 % 90 % 83 % 10 % no 295
Scognamiglio(2006) [16] 49 14 % 78 96 % 49 14 % 78 96 % 29 90 % 96 % 86 % 10 % yes 127
Nasr MR (2006) [17] 57 68 % 51 100 % 37 75 % 6 83 % 14 43 % 51 100 % 10 100 % 100 % 32 % 10 % no 108
Prasad ML (2005) [18] 123 11 % 85 66 % 88 15 % 19 10 % 14 0 % 2 0 % 6 50 % 67 72 % 8 50 % 13 79 % 66 % 89 % 10 % no 208
Casey MB (2003) [19] 30 40 % 30 100 % 30 40 % 30 100 % 100 % 60 % >0 % no 60
Erkilic S (2002) [20] 40 28 % 25 100 % 25 20 % 15 40 % 25 100 % 100 % 73 % NA no 65
Sahoo S (2001) [21] 20 100 % 15 100 % 20 100 % 15 100 % 10 100 % 100 % 0 % NA no 35
Cheung CC (2001) [22] 75 20 % 157 61 % 40 20 % 35 3 % 4 0 % 138 66 % 7 29 % 84 57 % 61 % 80 % NA no 232
Barut F (2010) [23] 393 22 % 65 92 % 22 50 % 283 0 % 8 50 % 10 50 % 55 100 % 14 100 % 92 % 78 % 10 % no 458
Wiseman SM (2008) [24] 100 46 % 105 95 % 95 % 54 % NA yes 205
Liu YY (2008) [25] 100 3 % 77 56 % 64 4 % 12 0 % 13 0 % 53 78 % 11 22 % 56 % 98 % other yes 177
Murphy K (2008) [26] 45 47 % 43 65 % 19 89 % 15 27 % 14 43 % 29 76 % 9 22 % 65 % 54 % >0 % yes 88
Nakamura N (2006) [27] 32 44 % 130 81 % 5 40 % 27 44 % 21 38 % 94 94 % 45 91 % 81 % 56 % 10 % yes 162
Rossi ED (2006) [28] 58 3 % 42 86 % 17 2 % 41 2 % 42 86 % 28 82 % 86 % 97 % NA no 100
Song Q (2011) [29] 151 26 % 441 96 % 97 26 % 54 24 % 441 96 % 96 % 74 % 10 % no 592
Beesley MF (2002) [30] 28 25 % 41 83 % 8 25 % 20 25 % 12 41 % 26 100 % 83 % 75 % >0 % no 69
de Matos PS (2005) [31] 210 7 % 129 54 % 170 0 % 18 33 % 12 17 % 38 21 % 84 73 % 25 52 % 54 % 93 % >0 % no 339
Nechifor-Boilă A (2014) [11] 11 0 % 11 45 % 3 0 % 5 0 % 11 46 % 5 0 % 45 % 100 % 10 % yes 22
Jang MH (2015) [32] 113 6 % 79 13 % 41 7 % 72 6 % 79 13 % 13 % 94 % 10 % yes 192
Yassin FE (2015) [33] 18 33 % 24 100 % 8 25 % 4 0 % 24 100 % 6 100 % 100 % 67 % >0 % no 42
Choi YL (2005) [34] 9 22 % 125 80 % 9 22 % 30 47 % 67 100 % 6 67 % 90 % 78 % 5 % no 134
Total 1941 2298 711 500 428 23 285 1764 45 357 4239
NG/N nodular goiter/normal, FA follicular adenoma, HA hyperplastic adenoma, HCA Hurthle cell adenoma, FTC follicular thyroid carcinoma, HCC Hurthle cell carcinoma, FVPTC folicular variant of papillary thyroid












Table 10 Sensitivity and specificity of HBME-1for malignancy, plus total number and percent of cases with positive immunoexpression
Reference Benign Malignant NG FA HA HCA FTC PTC HCC FVPTC Sens Spec
N % N % N % N % N % N % N % N % N % N % cut off TMA Total
Dunđerović (2015) 79 15 % 122 71 % 30 3 % 27 15 % 12 0 % 10 70 % 15 27 % 87 76 % 20 85 % 40 65 % 71 % 85 % 10 % yes 201
Barroeta (2006) [14] 53 10 % 37 70 % 4 25 % 3 33 % 18 6 % 3 0 % 7 71 % 11 91 % 4 25 % 4 75 % 70 % 90 % 25 % yes 90
Zhu X (2010) [15] 58 47 % 180 92 % 17 35 % 21 52 % 11 82 % 155 95 % 7 100 % 92 % 54 % 5 % no 238
Park YJ (2007) [10] 89 32 % 206 91 % 54 20 % 35 49 % 25 88 % 181 92 % 17 94 % 91 % 69 % 10 % no 295
Scognamiglio (2006) [16] 49 4 % 78 87 % 49 4 % 78 87 % 29 86 % 87 % 96 % 10 % yes 127
Nasr MR (2006) [17] 57 7 % 51 96 % 37 11 % 6 0 % 14 0 % 51 96 % 10 90 % 96 % 93 % 10 % no 108
Prasad ML (2005) [18] 123 2 % 92 72 % 88 1 % 19 10 % 14 0 % 2 0 % 6 50 % 67 85 % 8 13 % 13 93 % 72 % 98 % 10 % no 215
Casey MB (2003) [19] 30 3 % 30 100 % 30 3 % 30 100 % 100 % 97 % >0 % no 60
Cheung CC (2001) [22] 75 0 % 157 54 % 40 0 % 35 0 % 4 50 % 138 55 % 7 29 % 84 45 % 54 % 100 % ukn no 232
Barut F (2010) [23] 393 5 % 65 97 % 22 50 % 283 1 % 8 25 % 10 90 % 55 98 % 14 100 % 97 % 95 % 10 % no 458
Wiseman SM (2008) [24] 100 5 % 105 54 % 54 % 95 % ukn yes 205
Liu YY (2008) [25] 100 2 % 77 66 % 64 2 % 12 11 % 13 17 % 53 74 % 11 89 % 66 % 98 % other yes 177
Nakamura N (2006) [27] 32 9 % 130 77 % 5 0 % 27 11 % 21 38 % 94 97 % 45 96 % 77 % 91 % 10 % yes 162
Rossi ED (2006) [28] 58 2 % 42 93 % 17 2 % 41 0 % 42 93 % 28 93 % 93 % 98 % ukn no 100
de Matos PS (2005) [31] 210 11 % 129 80 % 170 0 % 18 56 % 12 33 % 38 63 % 84 94 % 25 84 % 80 % 89 % >0 % no 339
Nikiforova MN (2003) [36] 23 13 % 33 34 % 23 13 % 13 NA 33 34 % 19 NA 34 % 87 % 10 % no 56
Mai KT (2002) [37] 93 14 % 96 71 % 45 42 % 48 8 % 29 65 % 55 85 % 12 0 % 71 % 86 % >0 % no 189
Liang HS (2009) [38] 48 29 % 71 92 % 48 29 % 26 92 % 45 91 % 92 % 71 % 5 % yes 119
Ito Y (2005) [39] 253 26 % 175 69 % 155 30 % 98 17 % 138 61 % 37 100 % 69 % 74 % >0 % no 428
Mase T (2003) [40] 124 20 % 81 84 % 62 13 % 62 27 % 39 85 % 36 97 % 84 % 80 % 25 % no 205
Volante M (2004) [41] 50 12 % 102 53 % 50 12 % 32 88 % 70 37 % 53 % 88 % >0 % no 152
Nechifor-Boilă A (2014) [11] 11 27 % 11 64 % 3 33 % 5 40 % 11 64 % 5 60 % 64 % 73 % 10 % yes 22
Jang MH (2015) [32] 113 34 % 79 66 % 41 10 % 72 47 % 79 66 % 66 % 66 % 10 % yes 192
Guo Z (2015) [42] 52 0 % 85 77 % 20 0 % 32 0 % 28 40 % 57 96 % 29 92 % 77 % 100 % >0 % yes 137
Abd-El Raouf (2014) [35] 22 23 % 28 89 % 13 23 % 9 22 % 5 80 % 23 91 % 5 80 % 89 % 77 % 10 % no 50
Choi YL (2005) [34] 9 33 % 125 90 % 9 33 % 30 100 % 67 97 % 6 67 % 90 % 67 % 5 % no 134
Total 2304 2387 657 742 522 134 557 1489 146 366 77 % 89 % 4691
NG/N nodular goiter/normal, FA follicular adenoma, HA hyperplastic adenoma, HCA Hurthle cell adenoma, FTC follicular thyroid carcinoma, HCC Hurthle cell carcinoma, FVPTC folicular variant of papillary thyroid












Table 11 Sensitivity and specificity of Galectin 3 for malignancy, plus total number and percent of cases with positive immunoexpression
Reference Benign Malignant NG FA HA HCA FTC PTC HCC FVPTC
N % N % N % N % N % N % N % N % N % N % Sens Spec Cut
off
TMA Total
Dunđerović (2015) 79 35 % 122 89 % 30 13 % 27 41 % 12 67 % 10 50 % 15 73 % 87 92 % 20 85 % 40 93 % 89 % 65 % 10 % Yes 201
Barroeta et al. 2006 [14] 53 34 % 37 73 % 4 0 % 3 0 % 18 6 % 3 33 % 7 57 % 11 82 % 4 75 % 4 75 % 73 % 66 % 25 % Yes 90
Zhu X et al. 2010 [15] 58 34 % 180 86 % 17 24 % 21 14 % 11 64 % 155 92 % 100 % 86 % 66 % 5 % No 238
Park YJ et al. 2007 [10] 89 5 % 206 95 % 54 6 % 35 3 % 25 64 % 181 99 % 17 94 % 95 % 96 % 10 % No 295
Scognamiglio (2006) [16] 49 18 % 78 94 % 49 18 % 78 94 % 29 90 % 94 % 82 % 10 % Yes 127
Prasad ML e (2005) [18] 123 15 % 92 92 % 88 18 % 19 10 % 14 7 % 2 0 % 6 66 % 67 94 % 8 88 % 13 100 % 92 % 85 % 10 % No 215
Casey MB (2003) [19] 30 60 % 30 100 % 30 60 % 30 100 % 100 % 40 % 0 % No 60
Barut F (2010) [23] 393 4 % 65 94 % 22 36 % 283 0 % 8 25 % 10 90 % 55 95 % 14 98 % 94 % 96 % 10 % No 458
Wiseman SM (2008) [24] 100 23 % 105 87 % 87 % 77 % ukn Yes 205
Liu YY (2008) [25] 100 6 % 77 71 % 64 10 % 12 0 % 13 33 % 53 92 % 11 33 % 71 % 94 % other Yes 177
Murphy K (2008) [26] 45 42 % 43 65 % 19 42 % 15 33 % 14 21 % 29 86 % 9 55 % 65 % 58 % >0 % Yes 88
Nakamura N (2006) [27] 32 25 % 130 88 % 5 0 % 27 30 % 21 48 % 94 96 % 45 98 % 88 % 75 % 10 % Yes 162
Rossi ED (2006) [28] 58 0 % 42 88 % 17 0 % 41 0 % 42 88 % 28 86 % 88 % 100 % ukn No 100
Song Q (2011) [29] 151 51 % 441 97 % 97 52 % 54 48 % 441 97 % 97 % 49 % 10 % No 592
Beesley MF (2002) [30] 28 18 % 41 85 % 8 38 % 20 10 % 12 100 % 26 85 % 85 % 82 % >0 % No 69
de Matos PS (2005) [31] 210 5 % 129 53 % 170 0 % 18 11 % 12 8 % 38 21 % 84 73 % 25 52 % 53 % 95 % >0 % No 339
Nikiforova MN (2003) [36] 23 4 % 33 15 % 23 4 % 33 15 % 15 % 96 % 10 % No 56
Inohara H (2008) [45] 60 28 % 56 89 % 34 24 % 26 35 % 16 63 % 40 100 % 89 % 72 % >0 % No 116
Aiad HA (2008) [46] 38 11 % 41 93 % 19 11 % 19 11 % 13 92 % 28 93 % 93 % 90 % >0 % No 79
Sapio MR (2007) [47] 62 27 % 106 87 % 51 29 % 11 18 % 32 75 % 74 92 % 19 79 % 87 % 73 % 10 % No 168
Galusca B (2005) [48] 62 18 % 23 96 % 36 8 % 16 31 % 10 30 % 6 100 % 15 93 % 96 % 82 % >0 % No 85
Nucera C (2005) [49] 105 11 % 28 68 % 20 0 % 22 45 % 6 66 % 15 80 % 4 75 % 68 % 90 % NA NA 133
Weber KB (2004) [50] 13 31 % 33 79 % 13 31 % 9 44 % 24 92 % 79 % 69 % 5 % No 46
Oestreicher-Kedem (2004)
[70]
25 28 % 29 75 % 19 11 % 6 83 % 11 63 % 18 83 % 18 83 % 75 % 72 % 5 % No 54
Volante M (2004) [41] 50 12 % 102 95 % 50 12 % 32 97 % 70 94 % 95 % 88 % >0 % No 152
Torres-Cabala C (2004) [51] 91 9 % 60 77 % 57 0 % 12 17 % 14 0 % 3 33 % 13 62 % 34 91 % 4 100 % 12 92 % 77 % 91 % >0 % No 151
Lavra L (2011) [52] 14 0 % 29 93 % 14 0 % 3 67 % 24 96 % 2 100 % 9 100 % 93 % 100 % ukn No 43
Kovacs RB (2003) [53] 55 22 % 36 89 % 25 0 % 19 21 % 3 0 % 10 67 % 20 100 % 89 % 78 % >0 % No 91
Jakubiak-Wielganowiczv [54] 42 19 % 42 86 % 42 19 % 17 71 % 25 96 % 86 % 81 % >0 % No 84












Table 11 Sensitivity and specificity of Galectin 3 for malignancy, plus total number and percent of cases with positive immunoexpression (Continued)
Gaffney RL (2003) [56] 14 21 % 81 85 % 14 21 % 21 67 % 60 92 % 85 % 79 % other No 95
Martins L (2002) [57] 60 32 % 32 94 % 29 14 % 31 45 % 20 90 % 12 100 % 94 % 68 % other No 92
Coli A (2002) [58] 52 46 % 38 92 % 27 63 % 25 28 % 5 60 % 28 100 % 1 100 % 92 % 54 % >0 % No 90
Nascimento MC (2001) [59] 82 2 % 42 71 % 48 0 % 9 11 % 14 7 % 14 79 % 11 82 % 17 59 % 71 % 98 % >0 % No 124
Nechifor-Boilă A (2014) [11] 11 0 % 11 46 % 3 0 % 5 0 % 11 46 % 5 0 % 46 % 100 % 10 % Yes 22
Jang MH (2015) [32] 113 4 % 79 8 % 41 2 % 72 6 % 79 8 % 8 % 96 % 10 % Yes 192
Abd-El Raouf SM (2014) [35] 22 9 % 28 93 % 13 7 % 9 11 % 5 80 % 23 96 % 5 80 % 93 % 91 % 10 % No 50
Manivannan P (2012) [60] 12 17 % 10 100 % 3 100 % 7 100 % 100 % 83 % 10 % No 22
Total 2624 2802 932 748 466 106 488 1947 155 310 5426
NG/N nodular goiter/normal, FA follicular adenoma, HA hyperplastic adenoma, HCA Hurthle cell adenoma, FTC follicular thyroid carcinoma, HCC Hurthle cell carcinoma, FVPTC folicular variant of papillary thyroid












Table 12 Sensitivity and specificity for malignant cases of CD56 (total number and percent of cases with positive immunoexpression)
Reference Benign Malignant NG FA HA HCA FTC PTC HCC FVPTC
N % N % N % N % N % N % N % N % N % N % Sens Spec Cut off TMA Total
Dunđerović (2015) 79 92 % 122 42 % 30 87 % 27 96 % 12 100 % 10 90 % 15 73 % 87 25 % 20 90 % 40 38 % 58 % 92 % 10 % yes 201
Shahebrahimi K (2013) [64] 39 92 % 39 5 % 32 NA 7 NA 39 5 % 5 NA 95 % 92 % 0 % no 78
Nechifor-Boilă A (2014) [11] 11 64 % 11 18 % 3 33 % 5 60 % 11 18 % 5 20 % 82 % 64 % 10 % yes 22
Abd El Atti RM (2012) [65] 44 93 % 29 17 % 12 92 % 32 88 % 29 17 % 16 19 % 83 % 93 % 10 % no 73
Scarpino S (2007) [61] 107 100 % 66 27 % 26 100 % 61 30 % 21 10 % 73 % 100 % other no 173
ElDemellawy D (2009) [62] 100 100 % 75 0 % 2 NA 72 0 % 1 NA 23 0 % 100 % 100 % 10 % no 175
Satoh F (2001) [68] 11 46 % 39 8 % 11 46 % 10 0 % 14 7 % 92 % 46 % 0 % no 50
Park WY (2009) [63] 36 92 % 112 38 % 21 91 % 15 93 % 23 83 % 67 8 % 63 % 92 % 10 % no 148
Nechifor-Boila A (2013) [69] NA 83 % 204 15 % 204 15 % 90 27 % 85 % 83 % 10 % yes 204
Mi KS (2011) [66] 22 73 % 80 5 % 12 58 % 5 100 % 80 5 % 95 % 73 % 10 % no 102
Total 449 777 98 108 44 50 664 21 200 1226
NG/N nodular goiter/normal, FA follicular adenoma, HA hyperplastic adenoma, HCA Hurthle cell adenoma, FTC follicular thyroid carcinoma, HCC Hurthle cell carcinoma, FVPTC folicular variant of papillary thyroid












varied from 8–100 % (median = 88 %), and 40–100 %
(median = 82 %) for specificity. The average values were
not much different from median values (84 %; 83 %).
The percent of immunopositive cases for control groups
(non-tumour), follicular adenomas, follicular carcinomas
and papillary carcinomas have varied greatly: 0–52 %(me-
dian = 8 %);0–63 %(median = 17 %); 8–100 %(median =
66 %); 46–100 %(median = 93 %), respectively.
Three markers co-expression (HBME1,Gal-3,CK19)
had sensitivities of 83 %, 87 %, and 54 % as well as
specificities of 100 %, 89 % and 100 %, respectively [14,
16, 27]. Concurrent absence had sensitivity of 38% and
specificity of 100 % for benign [14].
In the study of Zhu X et al. [15], more than three im-
munohistochemical markers were simultaneously posi-
tive in 100 % of PTC cases and in 0–30 % of patients
with other types of disease.
CD56 is a neural cell adhesion molecule (NCAM),
which is expressed normally in thyroid follicular cells.
Reduced CD56 expression is correlated with tumour
progression of patients with cancer. Its expression is re-
duced, or totally lost, in cases of papillary carcinoma,
follicular carcinoma and anaplastic carcinoma [61–63].
The results of our study showed that malignant tu-
mours had lost or expressed CD56 less than benign thy-
roid lesions, which is in agreement with previously
published data [64–66]. CD56 expression is more re-
duced in papillary carcinomas in respect to follicular
carcinomas and follicular adenomas [62, 63].
On the other side, we had not found significant differ-
ence in CD56 expression between follicular variant of
papillary carcinoma and follicular carcinoma what is par-
tially supported with results of other study [67]. Intri-
guingly, we found the difference in expression between
follicular carcinoma and follicular adenoma, which is in
disagreement with results of other authors [62–64]. If
we connect previous information with findings that fol-
licular carcinomas has significantly reduced expression
of CD56 relative to benign follicular lesions we could
conclude that reduces expression of CD56 is not exclu-
sive property of papillary carcinoma.
Variation among studies in respect to sensitivity and
specificity was substantial [11, 61–66, 68, 69]. Sensitivity
for carcinoma varied from 58 to 100 % with a median
value of 84 % (recalculated average value for all studies
is 80 %). Specificity values ranged from 46 to 100 %, with
a median value of 92 % (recalculated average value for
all studies is 93 %).
The highest sensitivity this marker shows for papillary
carcinoma, and the lowest for follicular carcinoma.
Having in mind that we have obtained tissue cores
from tumour periphery, our results could be substanti-
ated by the results of other studies [61, 62], which found
that within the PTC groups, occasional CD56-positive
cells were identified, and in all cases, these cells were lo-
cated at the tumour/non-tumour interface. Therefore,
the low value of sensitivity (58 %) of CD56 in our inves-
tigation might be the result of tissue sampling.
Nechifor-Boilă A et al. [11] found that panels consist-
ing of CD56 and/or CK19/Gal-3 (they used Gal-3/CK19
formula because similar results were obtained in the
panels containing either CK19 or Gal-3), and CD56 and/
or HBME-1 had highest sensitivities (90.9 %) and nega-
tive predictive values (87.5 and 83.3, respectively), while
the most specific combination of markers was repre-
sented by association of HBME-1 with CK19/Gal-3
(72.7 %) in identifying PTC cases. The panel consisting
of CD56 and/or HMBE-1 was highly sensitive and spe-
cific (100 %, 90 %) in differentiating cases of FVPTC
from benign thyroid lesions/tumours. When three-
marker panels were evaluated, the best combination for
FVPTC cases was HBME-1, CD56 and/or CK19, with a
sensitivity reaching 91.1 % [69]. In the studies of Mi KS
et al. [66] and W Y Park et al. [63], sensitivities were
93,8 % and 88.1 % and specificities were 90.9 % and
93.8 % respectively, to distinguish PTC from other be-
nign thyroid lesions with the combination of three
markers CD56, GAL3, and CK19.
Table 13 Sensitivity and specificity (summary of all reviewed studies)
M/Ba PTC/FA FVPTC/ FA FVPTC/FTC FTC/FA PTC/NTb HCC/HCA
CK19 Sensitivity 80 % 90 % 74 % 74 % 28 % 90 % 51 %
Specificity 78 % 77 % 77 % 72 % 77 % 82 % 57 %
HBME1 Sensitivity 76 % 88 % 77 % 77 % 64 % 88 % 35 %
Specificity 87 % 73 % 73 % 36 % 73 % 93 % 57 %
GAL 3 Sensitivity 84 % 93 % 81 % 81 % 50 % 93 % 88 %
Specificity 83 % 78 % 78 % 50 % 78 % 86 % 77 %
CD56 Sensitivity 80 % 86 % 78 % 78 % 40 % 86 % 10 %
Specificity 93 % 83 % 83 % 60 % 83 % 54 % 90 %
aMalignant vs Benign; bPapillary thyroid carcinoma vs Non Tumor Tissue
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This marked heterogeneity of diagnostic value of in-
vestigated markers could stem from few reasons. Primar-
ily, cut off values varied from more than 0 to 25 % of
positive cells. Secondarily, some study designs included
other tumours beside well differentiated thyroid carcin-
omas. Further, there is still no consensus about technical
points, e.g., HMBE-1 membranous and/or cytoplasmatic
staining delivers significant amount of freedom in decid-
ing what is positive. Lastly, some studies employed TMA,
others not. At the end, there are results which showed
that more than one marker could be co-expressed even in
benign lesions, which oblige us to continue the quest of
searching more reliable markers. Until then, H&E slides
stays golden standard in diagnostics of follicular cells thy-
roid lesions.
It will not be fair not to mention weaknesses of this
study. We shed some light to tumour/normal tissue
interface, but we did not have proper representatives of
tissue from tumours core. The number of cases, espe-
cially Hurthle cell adenomas, and follicular adenomas,
was borderline. Some authors also claim that is mistake
to include Hurthle cell tumours, but from practical
standpoint, because we experienced real dilemmas if
tumour is papillary carcinoma (oncocytic variant) or
Hurthle cell adenoma for example, we included those tu-
mours also.
Conclusions
In conclusion we may say that Galectin 3 is most sensi-
tive marker for malignancy, while absence of expression
of CD56 is very specific for malignancy. Expected co-
expression for combinations of markers in diagnostics of
follicular lesions decrease sensitivity and increase specifi-
city for malignancy.
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